ArticleThe Journal of clinical investigation2021

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.

Jiawei Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.